<DOC>
	<DOC>NCT00121056</DOC>
	<brief_summary>The purpose of this study is to determine if Enbrel® or Kineret® will have a positive effect on subject functionality as measured by the Health Assessment Questionnaire Disability Index (HAQDI).</brief_summary>
	<brief_title>REKinDLE: Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations</brief_title>
	<detailed_description />
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Subjects with active rheumatoid arthritis as defined by ACR criteria Able to start Enbrel® or Kineret® therapy (per the approved product monographs) within approximately 30 days of confirmed enrolment Active infections at the time of initiating Enbrel® or Kineret® therapy Malignancy other than basal cell carcinoma of the skin or, in situ carcinoma of the cervix, within the past 5 years Known hypersensitivity to E. coli derived products Known hypersensitivity to Enbrel® or any of its components Subjects receiving, or who received:* Enbrel® in the previous 30 days; * Remicade® in the previous 3 months; * Humira® in the previous 3 months; * Kineret® in the previous 15 days. Subjects beginning Enbrel® therapy, or treated with prior or current treatment using Enbrel® Subjects beginning Kineret® therapy, or treated with prior or current treatment using Kineret® Treatment with any investigational therapy in the 30 days prior to enrolment confirmation Presence of any significant and uncontrolled medical condition which, in the investigator's opinion, precludes the use of Enbrel® Sepsis or at risk of septic syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>